QuickView for Wy-14643 (compound)

1. Hepatocytes treated with non-genotoxic carcinogens
2. HepG2 cells treated with genotoxic and non-genotoxic agents
3. Livers of CD-1 mice treated with genotoxic, non-genotoxic or non-hepatocarcinogens
4. Primary hepatocytes treated with non-genotoxic carcinogens or non-carcinogens
5. Embryonic stem cells treated with non-genotoxic carcinogens or non-carcinogens

1. Chronic Treatment With WY-14643 Induces Tumorigenesis and Triglyceride Accumulation in Mouse Livers.
2. PPARα agonist WY-14,643 enhances ethanol metabolism in mice: Role of catalase.
3. PPARα Agonist WY-14643 Relieves Neuropathic Pain through SIRT1-Mediated Deacetylation of NF-κB.
4. PPARα agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic f…
5. PPARα agonist WY-14,643 induces the PLA2/COX-2/ACOX1 pathway to enhance peroxisomal lipid metabolism…

There were no clinical trials for Wy-14643